Skip to content

Brenda Goodwin, MD

NPI 1033183462ActiveIndividual· Internal Medicine, Endocrinology, Diabetes & Metabolism· Chattanooga, TN

Internal Medicine, Endocrinology, Diabetes & Metabolism (MD) in Chattanooga, Tennessee, licensed in TN and AK, with an NPI issued in February 2006. Part D covered 1,384 prescriptions written in 2024, 38% of them generic. Novo Nordisk Inc was the largest of 13 companies reporting payments in 2025, $458.05 in all, mostly food and beverage.

Overview

NPI1033183462
StatusActive
Entity typeIndividual
CredentialMD
Sole proprietorYes
NPI issuedFeb 14, 2006
Last updated in NPPESApr 22, 2022
Certified by providerApr 22, 2022

Specialties and licenses

About license numbers in NPPES

Exclusion screening

ListResultDetails
HHS-OIG LEIE · Oct 9, 2026No matchChecked by NPI and by name + state
North Carolina Medicaid · Nov 10, 2026No match—
New York OMIG · Nov 10, 2026No match—
Ohio Medicaid · Nov 10, 2026No match—
Pennsylvania Medicheck · Nov 10, 2026No match—
Washington HCA · Nov 10, 2026No match—

Official OIG search · How matching works ·Bulk check a roster

Medicare

Enrollment (PECOS)Enrolled Practitioner - Endocrinology (TN)

Part D prescriptions in 2024

Prescriptions (claims)1,384 · 2,984 30-day fills
Patients233
Total drug cost$538,039
Generic share38% of claims

Medicare sources and data years

Industry payments (Open Payments)

  • 2025$458.05 · 28 payments from 13 companies
  • 2024$879.61 · 39 payments from 10 companies

Top paying companies in 2025

What the 2025 payments were for

  • Food and Beverage$458.05 · 28 payments

Receiving payments does not imply wrongdoing. What Open Payments covers ·original records

Other Internal Medicine, Endocrinology, Diabetes & Metabolism providers in Chattanooga

All Internal Medicine, Endocrinology, Diabetes & Metabolism providers in Tennessee →